Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.555 USD | -3.66% | +6.23% | -16.98% |
03:40pm | CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate | MT |
May. 23 | CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.98% | 827M | |
+51.94% | 63.85B | |
-2.34% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.21% | 26.52B | |
-21.53% | 18.69B | |
+2.83% | 12.73B | |
+22.29% | 12.11B | |
+27.57% | 12.07B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- Transcript : CureVac N.V., Q4 2023 Earnings Call, Apr 24, 2024